Data4Cure today announced a multi-year collaboration with Pfizer to deliver new biomedical insights using AI and the CURIE Knowledge Graph™ — spanning data harmonization, disease mechanisms, and target & biomarker identification.
Under the agreement, Pfizer teams will use the Biomedical Intelligence® Cloud to integrate and analyze multimodal data at scale, and to apply Data4Cure's graph-based AI to mechanism, subtype and indication-expansion questions.
“This partnership aims to address a critical challenge in pharmaceutical research: how to effectively turn vast and complex multimodal data into knowledge,” said Janusz Dutkowski, CEO and co-founder of Data4Cure. “We are excited to further enhance the platform's capabilities to provide Pfizer's researchers with new cutting-edge tools,” added Roy Ronen, CTO of Data4Cure.
Scope of the collaboration
- Data harmonization and multimodal data analysis
- Knowledge-graph AI and advanced analytics
- Disease mechanisms and disease subtypes
- Target and biomarker identification & indication-expansion studies
This capability enables our scientists to rapidly and easily compare results across studies to uncover insights.— Paul Rejto, VP, Discovery Technologies, Pfizer Oncology Research
Why it matters
Bringing harmonized data, a continuously updated knowledge graph and purpose-built AI into one environment shortens the path from question to grounded, traceable answer — at the scale a global R&D organization needs.
The collaboration builds on Data4Cure's work delivering contextualized, evidence-backed insights across the drug-development lifecycle. The companies presented initial results at the Precision Medicine World Conference (PMWC) 2025.